Treatment of Moderate to Severe Benign Prostatic Hyperplasia
Initial Treatment Selection
- The American Urological Association recommends alpha-adrenergic blockers as first-line medical therapy for patients with bothersome moderate to severe BPH symptoms, providing superior and more rapid symptom relief compared to other medical options, with a 4-6 point improvement in symptom scores within 2-4 weeks 1, 2
- Alpha-blockers demonstrate similar efficacy with a 4-6 point IPSS improvement, which patients perceive as meaningful, regardless of prostate size 1, 2
- The choice of alpha-blocker should be based on side effect profile, with options including tamsulosin, silodosin, doxazosin, terazosin, and alfuzosin, each with unique adverse effect profiles 1, 2
Critical Caveat for Cataract Surgery
- Patients should be asked about planned cataract surgery before initiating alpha-blockers, as these medications increase the risk of intraoperative floppy iris syndrome (IFIS) 1
When to Consider 5-Alpha-Reductase Inhibitors
- 5-ARIs, such as finasteride or dutasteride, should be reserved for patients with documented prostate enlargement who prefer to avoid alpha-blocker side effects, with a major advantage of reducing the risk of acute urinary retention and need for BPH-related surgery 1, 2
- 5-ARIs are less effective for symptom improvement, requiring 6 months to assess effectiveness, and have important counseling points, including sexual dysfunction and PSA decreases 1
Combination Therapy Strategy
- Combination therapy with an alpha-blocker and a 5-ARI should be prescribed for patients with enlarged prostates who are at risk of disease progression, to further reduce the risk of urinary retention and need for surgery beyond either monotherapy 1, 2
Absolute Indications for Surgical Referral
- Surgery is mandatory for patients with BPH-related complications, including refractory urinary retention, renal insufficiency, recurrent urinary tract infections, recurrent gross hematuria, and bladder stones clearly due to BPH 4, 5, 6, 2
Surgical Options
- TURP remains the benchmark surgical therapy with the strongest long-term efficacy data, while alternative surgical options include TUIP, transurethral electrovaporization, laser procedures, and open prostatectomy 1, 3
Follow-Up Protocol
- Treatment response should be monitored using IPSS scores and patient-reported global assessment, with continued therapy if the patient reports improvement matching IPSS improvement, and reassessment and discussion of alternative treatments if the patient reports a neutral or worsening response despite stable or improved IPSS 1